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Background: Cachexia affects most patients with incurable cancer. We hypothesize
that in metastatic cancer the mass of the tumor as well as its level of anaerobic
energy metabolism play a critical role in describing its energetic cost, which results
in elevated resting energy expenditure and glucose utilization, leading to cachexia.
Prior models of cancer cachexia may have underestimated the specific energetic cost
of cancer as they have not taken the range of tumor mass and anaerobic energy
metabolism fully into account.
Methods: We therefore modelled the energetic cost of cancer as a function of the
percentage of energy the cancer produces anaerobically, based on resting energy
expenditure, glucose turnover, glucose recycling, and oxygen consumption in cancer
patients found in previous studies.
Results: Data from two clinical studies where tumor burden was estimated and
resting energy expenditure or oxygen consumption were measured lead to a broad
range of estimates of tumor cost from 190 to 470 kcal/kg tumor/day. These values
will vary based of the percentage of energy the cancer produces anaerobically (from 0
to 100 %), which in and of itself can alter the cost over a 2 to 3-fold range. In addition
to the tumor cost/kg and the degree of anaerobic metabolism, the impact on a given
individual patient will depend on tumor burden, which can exceed 1 kg in advanced
metastatic disease. Considering these dimensions of tumor cost we are able to produce
a 2-dimensional map of potential values, with an overall range of 100–1400 kcal/day.
Conclusions: Quantifying the energetic cost of cancer may benefit an understanding
of the tumor’s causation of cachexia. Our estimates of the range of tumor cost include
values that are higher than prior estimates and suggest that in metastatic disease the
tumor cost could be expected to eclipse attempts to stabilize energy balance through
nutrition support or by drug therapies. Tumor mass and the percentage of anaerobic
metabolism in the tumor contribute to the cost of the tumor on the body and
potentially lead directly to negative energy balance and increased muscle wasting.Background
Cancer cachexia affects over 1.3 million people in the United States annually [1]. It is
associated with severe muscle wasting and reduced survival that cannot be fully re-
versed by nutritional support [2]. The causes of cachexia are complex and not well
understood [3], although its consequences are well documented. Cachexia is associated
with reduced caloric intake, inflammation, metabolic change, and fatigue [4]. It affects© 2015 Friesen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
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ation of decreased food intake and altered metabolism. This reduction in food intake can
arise from primary anorexia as well as symptoms arising from the tumor or side effects
from cancer treatment [6], although reduced food intake does not completely explain the
weight loss seen in cachexic patients [7]. In attempting to find the primary cause of cancer
cachexia, it has been suggested that cancer induces abnormalities in lipid, carbohydrate,
and protein metabolism, reduces the efficiency of energy metabolism, and this elevates
resting energy expenditure (REE), which may be a major determinant in patients develop-
ing cachexia [8]. Our paper builds upon the investigation of the contribution of cancer on
REE by investigating in greater depth the energy usage and substrate usage of tumors in
order to quantify the energy cost of cancer to the patient, to develop a better understand-
ing of the cause of cancer cachexia from an energetic perspective. The challenge in arriv-
ing at a cost estimate of cancer is that while in many studies the resting energy
expenditure (REE) of cancer patients is measured [8–10], uncoupling the energetic usage
of the body and that of the cancer is difficult. If the cancer is dispersed at several locations
its entire volume or mass is difficult to quantify, and the measurement of the specific
metabolic rate (i.e. energy cost/kg of tissue) of a tumor mass in vivo is technically challen-
ging in human subjects [11].
Tumors generally have a high uptake of glucose relative to most normal tissues, and
this is exploited clinically in the use of 18 F-deoxyglucose positron emission tomography
(FDG-PET) to detect cancer [12]. This upregulated glycolysis in cancer cells is a hall-
mark of cancer [13]. The high demand for glucose, even in the presence of adequate
oxygen, has been termed the Warburg effect. To what extent a tumor generates ATP
based on the glycolytic pathway converting glucose to pyruvate and then to lactate (an
anaerobic process) versus oxidative phosphorylation (an aerobic process) is difficult to
ascertain in vivo and likely varies considerably [11, 14]. In this paper, we refer to gly-
colysis as the pathway that converts glucose to lactate, generating 2 net ATP for the cell
(Fig. 1). Warburg estimated that highly glycolytic tumors may make as much as 50 % of
their ATP from glycolysis [15], although other researchers have found wide ranges of
values in vitro (0.31 to 80 %) [16, 17]. In vitro studies have limitations, as cells may have
increased glycolysis due to the artificial environment conducive to proliferation [18].
More relevant are recent studies examining the energy metabolism of tumors in situ,
obtained by infusing uniformly labeled 13C-glucose into cancer patients and thenFig. 1 Metabolic pathways that convert glucose and glutamine into lactate. Glucose is converted via
glycolysis to lactate, and glutamine through a truncated TCA cycle is able to be converted to lactate as well
via glutaminolysis. α-KG stands for alpha-ketoglutarate
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spectroscopy [11, 19, 20]. In brain tumors glycolysis was activated, though oxidative
phosphorylation (oxphos) was still intact [19]. In lung tumors glycolysis was elevated
compared to surrounding non-cancerous tissues [20]. Cancer patients exhibit increased
whole body glucose turnover [21–24], increased Cori cycle activity, where lactate is
recycled to glucose [21–23, 25], and increased gluconeogenesis [22, 25], suggesting that
in vivo glycolysis is elevated in many tumors. Additionally, microcalorimetric measure-
ments of isolated tumor and non-tumor tissue samples removed from humans showed
tumors having a higher metabolic rate, with increasing malignancy correlated with a
higher metabolic rate [26].
Glutamine is also converted into lactate in cancer cells in vitro, and in glioblastoma
cells it was found that ~60 % of glutamine was metabolized through glutaminolysis to
lactate [27] (Fig. 1). Anaerobic metabolism of glucose and glutamine in the tumor is
potentially a direct driver of muscle protein catabolism, as muscle is the major meta-
bolic source of carbon for gluconeogenesis and glutamine biosynthesis.
The clinical approach to abnormalities of human body weight is framed in the
concept of energy balance. A discrepancy between energy intake and energy expend-
iture results in cancer-associated weight loss, and to stop this (i.e. achieve weight
maintenance) or to reverse it and achieve weight gain, requires a quantitative under-
standing of both the energy costs of the body and those of the tumor. While it
might be important to know if total tumor cost was likely to be 10, 100 or
1000 kcal/day, we have no clearly defined theoretical framework to determine this
cost and therefore no clear clinical guideline of how much energy intake is required
to achieve the desired body weight goals. We therefore propose a quantitative theor-
etical model to estimate the energetic cost of a tumor in situ based on the percent-
age of energy generated by the tumor anaerobically. We estimate the energetic cost
of cancer based on resting energy expenditure (REE), glucose turnover, glucose re-
cycling, and oxygen consumption in cancer patients. REE is assessed by indirect cal-
orimetry, which measures oxygen consumption, carbon dioxide production, and
urea excretion to derive the energy usage of the body [28]. This analysis can help
explain how tumors directly impact elevated REE seen in cancer patients [10], which
may lead to cancer cachexia.The model
Mathematical model of tumor cost based on tumor energy metabolism
In order to quantify a possible cost of cancer based on the energy metabolism of tu-
mors in patients, we formulate a model of the energetic cost of cancer based on its
level of anaerobic energy production. Confusion has reigned on how to quantify the en-
ergetic cost of cancer in cachexic patients due to the complexity of correctly accounting
for the recycling of glucose when it is converted to lactate by the tumor and then recycled
primarily in the liver [29, 30]. We attempt to clarify this with our model, illustrated in
Fig. 2. A cancer patient may be considered a system comprising the host and tumor mass.
P denotes metabolic rate in kcal/day and K denotes the corresponding specific metabolic
rate, in kcal/day per kg patient, tumor or other specified mass. The cancer’s energetic de-
mand and growth will induce a cost on the normal body, and thus,
Fig. 2 The cost of aerobic and anaerobic metabolism of the tumor on the body. A tumor will consume
substrates both aerobically and anaerobically. The substrate usage of both an aerobic and an anaerobic
tumor is described. Anaerobic metabolism costs the body three times more energy due to the cost of
recycling lactate back into the glucose lost to the tumor (see Additional file 1 and equation (6)). The
substrate usage is equivalent to describe the metabolic rates of the aerobic and anaerobic tumor, which
leads to the definitions of the metabolic cost of the cancer on the body, Pcost, and the metabolic rate of the
tumor, Pcancer. The percentage of energy produced anaerobically by the tumor, Xanaerobic, is also illustrated
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where Pnormal is the metabolic rate of the person free of cancer, and Pcost is the ener-getic cost (in kcal/day) on the normal body caused by the cancer. Pcost is due to the
metabolic requirements of the tumor, an elevated Cori cycle with increased gluconeo-
genesis, an activated immune system, an acute phase response, and increased substrate
turnover [31–33]. In this paper, we investigate in detail the energetic cost of the tumor
by focusing on the metabolic requirements of the tumor and the resultant elevated Cori
cycle (Fig. 2). Normally, metabolic rates are determined based on oxygen consumption,
and it is assumed that all food (protein, carbohydrates, and fat) is completely oxidized
when the body is at rest. However, this is not the case for a tumor. We model a tumor
having an anaerobic component of its energy metabolism. Thus:
Pcancer ¼ Paerobic þ Panaerobic ð2Þ
where Paerobic is the aerobic component of a tumor’s metabolic rate, and Panaerobic is theanaerobic component of a tumor’s metabolic rate (Fig. 2). Now, we introduce:
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where Xanaerobic is the percentage of ATP energy generated anaerobically by the tumor
cell. Xanaerobic is a measure of how anaerobic the tumor is, and will be used extensively
in the analysis of how a tumor with a higher level of anaerobic metabolism will cost
the body more energy.
While theoretically aerobic metabolism generates 38 ATP per glucose, when account-
ing for energy loss in the respiratory chain, current estimates indicate around 30 ATP
are produced per glucose in oxidative phosphorylation [34]. Thus aerobic metabolism
generates 15 times the ATP that anaerobic metabolism generates per glucose (30 ATP
vs. 2 ATP). When energy is generated anaerobically by the tumor via glycolysis, 2 net
ATP are generated per glucose converted to lactate, and then 6 ATP are needed by the
body to reconvert the resulting lactate to glucose.
In a tumor producing energy 100 % aerobically, glucose from the body would be con-
verted into 30 ATP for use by the tumor, and CO2 would return to the host. Other oxi-
dized fuels from the body (such as glutamine and fatty acids) would also be obtained
from the bloodstream and these tumor-oxidized fuels would be lost to the body. Thus,
the cost of the tumor on the body, Pcost, would be Paerobic. However, a tumor that pro-
duces energy 100 % anaerobically from glucose and glutamine produces only lactate,
which will be recycled back into glucose in the liver and kidneys by the body via the
Cori cycle [30]. Thus, all the glucose consumed by the tumor would be recovered, at a
cost of 6 ATP per glucose used by the tumor. If a tumor consumed only glucose, a
100 % anaerobic tumor would consume 15 times the glucose that a 100 % aerobic
tumor would consume, but the glucose would be recycled in the Cori cycle. In the an-
aerobic case, the Cori cycle takes 6 ATP to generate 2 ATP for the tumor, and so the
energetic cost of the tumor is 3 times greater in the anaerobic case (see Additional file
1 for a more detailed derivation) (Fig. 2). Thus:
PCori ¼ 3Panaerobic ð4Þ
PCori is the energetic cost of Cori cycling lactate back into glucose (in kcal/day).
The energetic cost of cancer increases linearly as the percentage of energy derived
anaerobically by the tumor, Xanaerobic, increases. This can be expressed as follows:
Pcost ¼ Paerobic þ PCori ð5Þ
¼ Pcancer 1þ 2Xanaerobicð Þ ð6Þ
where Pcost is the metabolic cost of the cancer on the body due to the cancer’s metabolism
and the resultant Cori cycling that occurs to recycle the lactate produced by the cancer.
(see Additional file 1 for a complete derivation). Pcost can be rewritten as:
Pcost ¼ KcancerMcancer 1þ 2Xanaerobicð Þ ð7Þ
This gives the total energetic cost of cancer as a function of the specific metabolic
rate of cancer (Kcancer), the mass of cancer (Mcancer), and the percentage of ATP gener-
ated by the tumor anaerobically (Xanaerobic). We attempt to estimate a range of tumor
specific metabolic rates (Kcancer) from several previous studies using measurements of
REE and glucose turnover and Cori cycling activity, with the understanding that Kcancer
may vary greatly between patients and tumors due to tumor heterogeneity of the
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terms of glucose and oxygen availability.
Measurements currently performed when evaluating REE by indirect calorimetry,
REEIC, will determine the following:
REEIC ¼ Pnormal þ Pcost ð8Þ
¼ Pnormal þ Paerobic þ PCori ð9Þ
Measured REE reportedly increases with increasing tumor burden [32, 35], which will
be used to estimate Pcost. Cancer will tend to have effects on the body in terms of weight
loss, energy intake, cytokine production and an immune response, which may cause some
systems to consume less energy than normal, such as that for digestion and movement,
and some systems like the immune system to consume more energy. This has led to
conflicting results on whether cancer leads to increased REE or not [7, 10, 36]. These
values are not incorporated into Pcost in this analysis, and further studies would need to be
done to control for these variables.
Results
Estimates of energetic cost of cancer based on REE studies
The energetic cost of the tumor, Pcost, can be estimated by the increase in REEIC caused
by the tumor. There are currently limited studies that concurrently measure REEIC as
well as estimate tumor burden. Study A [35] evaluated a metastatic colorectal cancer
patient cohort (n = 18), with REE measurements and estimated mass of the combined
liver and metastases located in the liver, determined by computed tomography image ana-
lysis. Patient fat-free mass (FFM) was measured as well. There is a primary correlation
between REE and FFM, leading to the generalized prediction equation: REE = 370 +
21.6 × FFM (Cunningham equation) [37]. Healthy patients would also have liver mass
primarily proportional to their fat free mass (FFM) [38], and so an increased (liver +
metastases)/FFM value may be primarily due to increased cancer metastases. Thus we
plotted the given patient REE compared to their estimated combined liver and metas-
tases mass, adjusted for patient fat free mass (Fig. 3). We found:
REE kcal=dayð Þ=FFM kgð Þ assessed by indirect calorimetry
¼ 300 110 liverþmetastases mass; in kgð Þ=FFM Kgð Þ þ 20 r2 ¼ 0:32; p ¼ 0:01 
ð10Þ
It is important to note that there is a large standard error in this result. Ideally additionalstudies would be conducted to measure tumor mass and REE for patients over a time
course in order to test more precisely how tumor mass might correlate with REE. As the
liver’s metabolic rate is approximately 200 kcal/kg liver/day [39], a slope in Fig. 3 of
300 kcal/(kg liver +metastases)/day would potentially indicate the energetic cost of metas-
tases is higher than 200 kcal/kg metastases/day. If we assume the increased REE after
controlling for LBM is primarily due to metastases, then, as in our model, from equation
(8) the specific total cost of the tumor from this study is (to 2 significant figures):
Kcost ¼ 300 110 kcal=kg tumor=day Study Að Þ ð11Þ
Again, this value must be used with caution due to the large standard error and impre-cision in measuring tumor mass. However, we use this result to illustrate how our model
Fig. 3 Impact of increased tumor mass on resting energy expenditure. Plot of resting energy expenditure
(REE) and liver & metastases mass from the prospective colorectal cancer patient cohort (n = 18) found in
[35]. The values have been adjusted for variations in fat free mass (FFM) of the patient cohort. Simple linear
regression found: REE/FFM (kcal/kg/day) = (300 ± 110) * (Liver +Metastases mass) (kg)/FFM (kg) + 30 (r2 = 0.32,
p = 0.01). Future studies to reduce the standard error of this result are recommended
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tumor/day (Fig. 3), provided we know the percentage of ATP generated by glycolysis from
the tumor. We make the initial assumption that 25 % of ATP is generated by glycolysis
(Xanaerobic =0.25), as this is in line with in vitro estimates from cell lines derived from
metastatic adenocarcinoma of the colon [40] and other cell lines where many estimates
range from 20 to 75 % [41–43]. A value of 25 % anaerobic ATP synthesis is also consistent
with preliminary in situ reports and in vivo data on glucose turnover and Cori cycling
[23]. This corresponds to 50 % of the tumor-associated REE, Kcost, due to Cori cycling and
50 % due to the aerobic component of tumor energy metabolism, if we neglect other
factors that might increase REE as a result of the tumor (Additional file 2: Table S1
displays the relative Paerobic and PCori based on Xanaerobic). Thus:
Kaerobic ¼ 150 55 kcal=kg tumor=day ð12Þ
KCori ¼ 150 55 kcal=kg tumor=day ð13Þ
From this we obtain:Kanaerobic ¼ 50 18 kcal=kg tumor=day ð14Þ
Kcancer ¼ 200 73 kcal=kg tumor=day ð15Þ
As these results are calculated scalar multiples of Kcost (see Additional file 2), the
standard error in these values are multiples of the standard error of Kcost. This value of
Kcancer is higher than the previous assumption used by Hall of Kcancer = 150 kcal/kg/day
[31], and is roughly equal to the metabolic rate of liver (Table 1) [39].
Another study related tumor mass with whole body oxygen consumption over a wide
variety of types of cancers (Study B) [32]. Tumor mass was assessed by reviewing
dimensions of tumors in resected specimens, as well as estimating volumes from
ultrasound and computed tomographic scanning. Oxygen consumption was measured
by indirect calorimetry. Their data corresponds to an oxidative metabolic increase of











Cancer: Study A [35] 150 ± 55 50 ± 18 200 ± 73 150 ± 55 300 ± 110
Cancer: Study B [32] 200 to 230 50 to 80 270 to 310 200 to 230 400 to 470
Liver [39] 200 0 200 0 200
Heart [39] 440 0 440 0 440
Kidney [39] 440 0 440 0 440
Brain [39] 240 0 240 0 240
Skeletal muscle [39] 13 0 13 0 13
The specific energetic cost of cancer, with Xanaerobic = 25 %, are compared with various other organs. Typical organs are
assumed to have complete oxidation. Cost is rounded to two significant figures. Study A was a study of n = 18 metastatic
colorectal cancer patients [35]. Study B was a study of n = 85 cancer patients studied preoperatively, with a majority of
patients having solid tumors of the gastrointestinal tract, retroperitoneum, or limbs [32]. Ranges of cost were given due
to patient mass in the studies not being provided. Details of calculations involved in Kcost for Study B are detailed in
Additional file 3, and were based on the plot of oxygen consumption of patients and their tumor bulk with r2 = 0.79.
Estimates of energetic costs of cancer should be taken with caution, as they could be highly variable due to the type of
cancer studied
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culations) [44]. Patient body mass data was not provided in Study B; however, assuming
average patient weight between 60 and 70 kgs, the Kcost in Study B is estimated between
400 and 470 kcal/kg tumor/day (see Additional file 3). If again, ATP from glycolysis is esti-
mated at 25 % for the tumor, this corresponds to Kcancer in the range of 270 to 310 kcal/
kg/day (equation (6)). This estimate for specific metabolic rate of cancer falls within the
range of previous estimates (150 to 406 kcal/kg/day [31, 35, 45]) (Table 1).
Estimates of energetic cost of cancer based on substrate usage
Another method to estimate specific tumor metabolic cost is to analyze glucose turnover
in the body (i.e. rate of glucose entering and exiting the bloodstream) and the rate of Cori
cycling (Fig. 4). Glucose is one of the primary sources of fuel for a tumor cell [43], and so
estimating the glucose usage of the tumor will provide an estimate of a percentage of the
total energy usage of the tumor. Glucose enters the bloodstream primarily from food (Fg),
glycogen stores (Sg), de novo gluconeogenesis (Dg), and Cori cycling (Cg). Glucose is used
by the body’s organs (Og), and may be stored as glycogen in the liver (Gg), converted to tri-
glyceride and stored in adipose tissue (Ag), or used by a tumor (Tg). The rate of all of these
processes, at any given time, is
Fg þ Cg þ Dg þ Sg ¼ Og þ Tg þ Ag þ Gg ð16Þ
if we assume a static level of glucose in the blood. In a healthy person in the fed state, Fg
will be high, Cg, Dg, and Sg will be essentially zero and storage (Gg, Ag) will occur. During
early fasting, liver glycogen is mobilized to maintain blood glucose levels, and after a fast
of 4–6 h, gluconeogenesis from the catabolism of muscle protein and glycerol from trigly-
ceride will increasingly sustain blood glucose levels.
In the case of a patient with a tumor, Tg will be high continuously. Consider
Tg ¼ Tanaerobic þ Taerobic ð17Þ
where Tanaerobic is the rate of glucose uptake by the tumor converted to lactate andTaerobic is the rate of glucose that is used by the tumor to generate energy by oxidative
Fig. 4 A model of glucose turnover in the bloodstream. The tumor, by consuming glucose at an elevated
rate, Tg, may lead to increased de novo glucose production, Dg (ie. muscle and fat catabolism), in fasting
periods. This may be a large contributor to cachexia. As well, the Cori cycling rate, Cg, a function of how
much glucose is recycled in the liver from lactate generated from the body, leads to increased energy
demand on the body when the tumor exports lactate due to its high rate of glycolysis. The liver glycogen
buffer stores approximately 100-120 g of glucose
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becomes:
Fg þ Dg þ Sg ¼ Og þ Taerobic þ Ag þ Gg ð18Þ
Taerobic will provide a constant drain on overall glucose supply, necessitate additional
gluconeogenesis and correspondingly deplete gluconeogenic precursors, as Og, Ag, and
Gg will be reduced. All these factors may result in reduced liver glycogen stores, which
have been reported in cachexic patients [22] and mice with cachexia-inducing C26
colon adenocarcinoma [47]. During fasting, Cg will supply some of the needed glucose,
but as Fg is zero, and glycogen stores may be low, the tumor may increasingly rely on
glucose originating from de novo gluconeogenesis, Dg.
While a tumor has multiple fuels including glucose, glutamine, and fatty acids, if we
analyze glucose turnover and glucose recycling, we can estimate the component of Pcost
due to tumor glucose consumption, which we define as Pcost_glucose (see Additional file 4
for details on these calculations). Multiple studies gave measurements of glucose turnover
and glucose recycling in cachexic patients, leading to our computation of estimates of
Pcost_glucose in Table 2. Study C [23] compared patients with metastatic carcinoma who had
progressive weight loss or were weight stable, and we calculate a Pcost_glucose = 200 kcal/day.
Study D [22] compared cachexic metastatic colorectal cancer patients versus an age-related
control group without cancer, with a calculated Pcost_glucose = 94 kcal/day. Study E [21]
compared malnourished cachexic cancer patients versus malnourished patients
without cancer, where all patients had lost ~14-15 % of their normal body weight,
with a Pcost_glucose = 240 kcal/day.
The average of the studies C, D, and E gives an estimate of Pcost_glucose of 180 kcal/day
for a 70 kg patient while fasting, although an estimate of the size of the tumors in these
studies is not provided and so Kcost_glucose of the cancer cannot be calculated from these
studies. Study B [32] related plasma glucose appearance to estimated mass of tumor in
85 cancer patients. From their data we calculate Kcost_glucose in the range of 220 to
260 kcal/kg tumor/day based on increased plasma glucose appearance dependent on
tumor mass, and the assumption that 25 % of tumor ATP was generated anaerobically











Cost estimate of tumor based on
glucose turnover and glucose
recycling (for 70 kg patient)
C [23] 2.06 g/kg
patient/day
44 % 26 % Pcost_glucose = 200 kcal/day
D [22] 0.850 g/kg
patient/day
26 % 19 % Pcost_glucose = 94 kcal/day
E [21] 1.19 g/kg
patient/day
27 % 4 % Pcost_glucose = 240 kcal/day
Additional information about the calculation of pcancer, Xanaerobic, Kcost, and Pcost_glucose are found in Additional file 4. Cost is
rounded to two significant figures. Study C [23] compared patients with metastatic carcinoma who had progressive weight
loss or were weight stable. Study D [22] compared cachexic metastatic colorectal cancer patients versus an age-related
control group without cancer. Study E [21] compared malnourished cachexic cancer patients versus malnourished patients
without cancer, where all patients had lost ~14-15 % of their normal body weight
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55 % of Kcost in Study B.
Tumor energetic cost
Table 3 summarizes estimates of the cost of the tumor on the body, Kcost. The range of
costs from REE and oxygen consumption is 190 to 470 kcal/kg tumor/day. This is a
large range and further studies must incorporate estimates of tumor mass in order to
derive more accurate values for Kcost. However, analyzing this energetic cost, even with
its current large uncertainty, is instructive in appreciating the potential importance of
understanding this energetic cost of the tumor. Kleiber’s formula for estimating the
reference man’s basal metabolic rate simplifies to [48]:
Pnormal ¼ 69:6M0:75 ð19Þ
Thus, in our model, using the representative value of Kcost being 300 kcal/kg tumor/dayfrom Study A, this leads to the metabolic rate of a cancer patient to be:
P ¼ Pnormal þ Pcost ¼ 69:9M0:75 þ 300Mcancer ð20Þ
where M =Mnormal. We note the high coefficient based on tumor mass, and the fact
that the cost scales linearly to the tumor mass.
To assess the range of values of the cost of the tumor, Pcost, we plot equation (7),Table 3 Estimates of Kcost and Kcancer
Study and parameter
measured in study
Estimated cost of cancer, Kcost
(kcal/kg/day)
Equivalent Kcancer assuming Xanaerobic = 25 %
(kcal/kg/day)
A [35]: REE increase 300 ± 110 200 ± 73
B [32]: increased oxygen
consumption
400 to 470 270 to 310
Estimates are summarized of tumor cost on body per kg tumor. The equivalent Kcancer using Xanaerobic = 25 % is shown
(calculated from equation 6). Study A derives this estimate from increased resting energy expenditure (REE) per kg (liver
+ metastases) adjusted for variations in fat free mass (FFM) in a prospective colorectal cancer patient cohort (n = 18)
found in [35], and Study B derives this estimate from increased oxygen consumption per kg tumor (see Additional file 3),
in a study of n = 85 cancer patients studied preoperatively [32]. Ranges of cost in Study B were given due to patient
mass in the studies not being provided. Cost is rounded to two significant figures. Estimates of energetic costs of cancer
should be taken with caution, as they could be highly variable due to the type of cancer studied
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using Kcancer = 200 kcal/kg tumor/day calculated from Study A, and a range of clinically
plausible values of the mass of the cancer, Mcancer, and the percentage of ATP generated
anaerobically by the tumor, Xanaerobic (Fig. 5). Study A [35] provided an analysis of
a retrospective colorectal cancer cohort (n = 30) of patients, tracking their liver +
metastases mass over the final 12 months of their disease. As liver mass was as-
sumed to be constant, we could provide an estimate of metastases mass at the
endpoint of the disease, and these masses are plotted in red in Fig. 5, where we use the
previous assumption that Xanaerobic = 0.25 for these patients. In early stage cancers, the
cost of the tumor will likely be in the lower-left quadrant of Fig. 5 but for extensive meta-
static disease, the tumor cost would extend towards the upper-right quadrant [32, 49, 50].
The potentially large energetic cost of the tumor may help explain cachexia in advanced
metastatic disease. A disseminated metastatic tumor weighing 1.8 kg which makes 25 %
of its ATP from glycolysis could plausibly cost ~540 kcal/day, i.e. 32 % of the basal
metabolic rate of the reference man. Such high levels of tumor energy expenditure, often
in the context of profound anorexia, would drive proteolysis and lipolysis. This model of
cachexia is summarized in Fig. 6.Fig. 5 Contour plot of the estimated energetic tumor cost based on energy metabolism and tumor mass.
The estimated energetic cost of the tumor, Pcost, in kcal/day, is plotted based on its mass, Mcancer, and the
percentage of ATP the tumor generates anaerobically through glycolysis, Xanaerobic. The plot uses equation
(7), with Kcancer = 200 kcal/kg tumor/day found in Study A (see Table 3). Early stage tumors may not present
a high cost, but as tumors grow and become more glycolytic, their cost will increase and may induce a
catabolic, cachexic state. Patients from the retrospective colorectal cancer cohort in [35], n = 30 (Study A)
are plotted in red, with assumed 25 % ATP generated by glycolysis, where tumor mass is estimated by
taking their final (liver + metastases) mass and subtracting the initial (liver + metastases) mass in the final 12
months of their disease. This is to provide an illustration of where cachexic patients may fit within this map
and should only be considered as a very rough estimate of tumor energetic cost. For the thirty patients, the
mean tumor burden is 0.83 kg (equivalent to a cost of 250 kcal/day), standard deviation is 1.06 kg, and a
patient with estimated tumor mass of 4.7 kg, outside the axis of the figure, is not shown
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While a tumor may have a high energetic cost, its cost may not be readily apparent as
measured by indirect calorimetry, because while a tumor might have a high energy
usage, owing to depletion of lean and fat tissues the body may be correspondingly con-
suming less energy. By analyzing glucose turnover and Cori cycling we can estimate the
percentage of energy from glucose lost to the tumor, which may be a parameter better
suited to predict cachexia based on tumor energetic cost.
The probability that glucose is consumed by a tumor, pcancer, can be estimated as the
increased glucose turnover in cancer patients compared to the glucose turnover of the
patient:
pcancer ¼ tcancer−tcontrolð Þ=tcancer ð21Þ
where tcancer is the glucose turnover rate in cancer patients and tcontrol is glucose turn-over rate in healthy controls. pcancer ranged from 26 to 44 % in studies C-E (Table 2).
The estimate of the percentage of glucose converted to lactate by tumors, panaerobic, can
be estimated as the increased Cori cycling in cancer patients (indicating the amount of
glucose used by the tumor anaerobically) compared to the increased glucose turnover
(indicating the amount of glucose used by the tumor):
panaerobic ¼ Ccancer−Ccontrolð Þ= tcancer−tcontrolð Þ ð22Þ
where Ccancer is the Cori cycling rate of glucose in cancer patients and Ccontrol is the
Cori cycling rate of glucose in healthy controls. panaerobic ranged from 40 to 84 % in
studies C-E (Table 2). These values of panaerobic correspond to 4 to 26 % of ATP gener-
ated from glycolysis (Xanaerobic) (Table 2 and Additional file 4). A tumor has a much
higher panaerobic than Xanaerobic as the ATP generated anaerobically per glucose is 15
times less than that of ATP generated aerobically from glucose (see Additional file 4 for
the exact conversion formula).
The expected ATP generated for the body per glucose entering the bloodstream
(energetic payout of a glucose), g(pcancer, panaerobic), can be estimated by assuming
that 30 ATP will be generated per glucose consumed by the body [34], and that 6Fig. 6 The proposed model of the tumor causing an energy deficit leading to cachexia. The tumor’s large
consumption of glucose and glutamine, and conversion of these substrates to lactate which then require
energy from the body to convert back to glucose, creates a vicious cycle of lost energy. Muscle breakdown
would provide glucose and glutamine to feed the tumor, especially in a fasting state
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will be generated if the glucose is lost to the tumor aerobically (see Additional file 5
for more information on the definition of g(pcancer, panaerobic)). The percentage of
energy lost to the body per glucose entering the bloodstream, plost, is then determined
from g(pcancer, panaerobic) (see Additional file 5). plost is plotted in Fig. 7. The values of
pcancer and Xanaerobic are calculated for studies C-E in order to find plost for these
studies (see Table 2). Study C compared cachexic cancer patients to weight-stable
cancer patients and showed an additional 23 % of energy from glucose lost. Studies D
and E, which compared cancer patients to normal controls showed 12 % and 21 % of
energy from glucose lost to the tumor, respectively.
Discussion
We used a variety of currently available evidence for REE, glucose turnover, Cori cyc-
ling rate, and tumor burden to obtain our main result to estimate a tumor’s energy cost
on the body, Pcost, based on tumor mass (Mcancer), the percentage of ATP synthesized
anaerobically in the tumor (Xanaerobic), and the specific metabolic rate of the cancer
(Kcancer) (Fig. 5). The first dimension of the map (Mcancer) encompasses a range of clin-
ically plausible tumor burdens up to 3 kg [32, 51]; the second dimension is Xanaerobic
over a range primarily seen in cancer cell lines [14–16], and we use a base value of
Kcancer = 200 kcal/kg tumor/day estimated from Study A [35]. This map provides a
range of estimates, which may be considered within the limitation that data sets which
include all of the relevant parameters: Mcancer, Xanaerobic, and Kcancer, with known REE
values over the time course of the disease, are not readily available. In future studies,Fig. 7 Contour plot of the percentage of glucose energy lost to tumor, plost. plost is indicated on the graph for
studies C-E based on the probability the glucose in the bloodstream enters the tumor, pcancer, and the percentage
of ATP derived by glycolysis in the tumor, Xanaerobic. Study C compared cachexic cancer patients
versus weight-stable cancer patients. Studies D and E compared cachexic cancer patients versus normal controls.
In study E both cachexic cancer patients and normal controls were 14-15 % under their normal weight
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sion tomography/computed tomography (PET/CT) scan analysis [52]. Xanaerobic and
Kcancer are difficult to evaluate empirically in a direct manner, with current efforts
involving in vivo isotope labelling, primarily with 13C-glucose [11]. In human cancers,
Xanaerobic, could be lower or higher than the base value we used in our model (25 %),
and could also vary over time and even within a tumor [11]. Within those caveats, esti-
mates of Pcost are higher than previously considered [31, 35]. Consider a metastatic
colon cancer patient with the average tumor burden of the sample in Fig. 5, for which
the energetic cost of the tumor would likely fall in the range of 180–500 kcal/day,
depending on the proportion of ATP synthesized anaerobically within that tumor mass.
At the distal ends of the tumor mass distribution in the patient sample, there are indi-
viduals whose tumor cost would be < 200 kcal/day in any instance, and others whose
tumor cost could be in excess of 400 kcal/day and potentially over 800 kcal/day if
largely anaerobic. These estimates of tumor energy demand are useful in achieving
understanding of the scope of potential tumor contribution to the body’s energetic
deficit. The absolute cost of a tumor will have a variable impact on patients depending
on their REE which is largely dependent on body mass. For instance, a tumor cost of
300 kcal/day will be 25 % of REE of a patient with a normal REE of 1200 kcal/day, but
only 15 % of REE for a patient with a normal REE of 2000 kcal/day.
The estimate of % ATP synthesis generated anaerobically, Xanaerobic, is a large
assumption of our model, and further information on tumor metabolism in situ in
humans is needed to refine this number for various cancers and at various stages of
disease progression [11]. Drug-resistant, aggressive tumors found in late stage cancer
patients may have a higher rate of glycolysis [26, 53]. A study to investigate energy
consumption in the resting versus proliferating state, using mitogen-activated rat
thymocytes, found cells in the proliferating state consumed 4.9 times the ATP as those
in the resting state, with 86 % of ATP generated from glycolysis in the proliferating
state versus only 12 % of ATP generated from glycolysis in the resting state [54]. Thus,
rapidly proliferating tumors may have increased Xanaerobic and Kcancer, which would
drive Pcost higher according to equation (7). This is consistent with findings of elevated
REE for newly diagnosed stage IV cancer patients compared with newly diagnosed stage
I-III cancer patients [8].
Analyzing glucose turnover and glucose recycling also approximated the energetic
cost of cancer where glucose is the energy substrate, Pcost_glucose, in Table 2. These
calculations, perhaps more importantly, allow us to approximate the percentage of en-
ergy taken from the body from glucose by the cancer. Approximately 10-25 % of energy
derived from glucose is lost to the tumor in cachexic cancer patients (Fig. 7). This may
lead to muscle wasting to generate more glucose to make up for this loss of energy. It
also suggests a further avenue of study to test for a critical percentage of energy from
glucose lost, plost, which overloads the body’s ability to maintain adequate glucose to
the body without resorting to excessive gluconeogenesis and muscle wasting. In effect,
we hypothesize this parameter, plost, may be a predictor for the onset of cachexia.
Our model develops further the previous model of Hall and Baracos [31] by refining
estimates of the cost of the tumor because of the tumor’s increased glucose consump-
tion, and incorporates the possibility that a tumor may vary in the proportion of
oxidative and glycolytic metabolism. Hall et al. [31] modeled the change in lipolysis,
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and their effects on resting metabolic rate and gluconeogenesis. The model incorpo-
rated the cost of elevated glycogen, fat, and protein turnover and lipolysis and prote-
olysis. It also incorporated the cost of the tumor in terms of Cori cycling cost, which
was estimated to start at 16 kcal/day and increased to 64 kcal/day, and assumed a
specific metabolic cost of the tumor at 150 kcal/kg/day based on experimental stud-
ies. Our model refines this to a base estimate of Kaerobic = 150 kcal/kg/day, and KCori
based on the level of glycolysis in the cancer, with a base estimate of 150 kcal/kg/day,
for a combined total cost, Kcost, of 300 kcal/kg/day (Study A). Based on this Kcost, and
assuming Xanaerobic is 25 %, the actual specific metabolic rate of cancer, Kcancer, here is
estimated at 200 kcal/kg/day.Implications of tumor anaerobic metabolism for skeletal muscle loss
Anaerobic metabolism may drive additional gluconeogenesis, due to the increased
usage of glucose and glutamine. Cancer is suggested to act as a “glutamine trap,”
leading to a transfer of nitrogen from muscle to the tumor [55]. Cultured tumor
cells require ten times as much glutamine as any other amino acid [27] and more
than 90 % of the body’s glutamine stores are in the muscle [56]. It is now recog-
nized that glucose and glutamine are the main sources of energy for cancer cells
[27, 43], although this has yet to be conclusively established in vivo. Since skeletal
muscle–derived amino acids are the major precursors of glutamine synthesis as
well as the main source of carbon for gluconeogenesis, muscle protein catabolism
may be driven by tumor consumption of these substrates.Clinical implications
A dilemma in treating patients with cachexia is that an increase in caloric con-
sumption reduces or slows weight loss but does not typically lead to weight gain
[57, 58]. This raises the question as to exactly how much energy intake would be
required to result in weight stability or restore positive energy balance. Improved
volitional energy intake that is achieved with dietary consultation and oral
nutritional supplements can reach between 500 and 600 kcal/day [59, 60]. This
type of intervention has documented clinical benefits and is most successful during
radiation and chemotherapy with curative intent, while the tumor is responding to
treatment. Indications for non-volitional (artificial enteral/parenteral) feeding are
specified within published clinical practice guidelines [61, 62], according to their
potential benefits and risks. The reference range of tumor energy expenditure
(Fig. 5) should help frame clinical expectations. For the patient with limited tumor
burden or whose disease is controlled by anticancer therapy, reduced weight loss
or weight stability could be achievable within a realizable set of nutritional goals.
Patients undergoing an objective tumor response during treatment (tumor shrink-
age) would be expected to have a reduced tumor energy demand compared to a
rapidly proliferating tumor. Aligned with the concept of refractory cachexia [2] for
the patient whose cancer is metastatic, very large and growing in spite of cancer
therapy, the tumor cost would be expected to eclipse attempts to stabilize energy
balance through volitional food intake, or even by means of artificial nutrition.
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catabolic mediators (ie. cytokines, myostatin) that activate proteolysis and lipolysis,
without addressing the energetic burden of the cancer will potentially have limited
impact.Conclusions
We have calculated the energetic cost of cancer based on the cancer’s specific meta-
bolic rate and level of anaerobic energy production, and estimated this cost based on
clinical data, reaching the conclusion that tumor cost may be considerably higher
than previously assumed in patients with metastatic disease. High glucose turnover as
a result of anaerobic energy production has the potential to result in cachexia due the
high constant demand for glucose from the tumor, especially in the fasting state. Our
models in Figs. 2 and 4 provide a framework for better understanding the role of
anaerobic energy production in cancer in affecting the energy balance in cancer
patients. Our estimates of the energetic cost of tumors as a function of anaerobic
energy production in the tumor in Fig. 5 and equation 7 suggest that reduction in
anaerobic tumor ATP synthesis may mitigate tumor cost. At present we do not have a
means of convincing a tumor to switch to aerobic metabolism, although this becomes
a topic of interest now that we understand that such an intervention could have a
quantitatively important impact on energy balance. While it is generally understood
that hypermetabolism is common in advanced cancer patients [10, 63], future studies
should attempt to estimate tumor burden, tumor energy consumption through
indirect calorimetry, tumor substrate utilization, and ideally liver glycogen reserves at
different stages of cancer disease progression in order to better understand the
tumor’s energy consumption as a cause of hypermetabolism and weight loss.
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